AOMS1
MCID: ABD014
MIFTS: 62

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 57 12 15
Metabolic Syndrome X 57 12 76 29 55 40 73
Metabolic Syndrome 44 63
Abdominal Obesity Metabolic Syndrome 73
Dysmetabolic Syndrome X 12
Aoms1 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 605552
Disease Ontology 12 DOID:14221
ICD10 33 E88.81
ICD9CM 35 277.7
MeSH 44 D024821
NCIt 50 C84442
MedGen 42 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 57 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and fatty liver disease, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Developmental Biology and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). Affiliated tissues include liver, endothelial and heart, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 63 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease.In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries.Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 76 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 485)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.0 AOMS1 HSD11B1 INS LEP SLC2A4
2 fatty liver disease 31.5 ADIPOQ INS LEP
3 liver disease 30.2 ADIPOQ INS LEP MEG3
4 sleep apnea 30.0 ADIPOQ INS LEP
5 nonalcoholic steatohepatitis 30.0 ADIPOQ INS LEP
6 hyperinsulinism 29.9 INS LEP SERPINE1
7 chronic kidney failure 29.8 ADIPOQ INS LEP
8 apnea, obstructive sleep 29.8 ADIPOQ INS LEP
9 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 29.7 ADIPOQ INS
10 nonalcoholic fatty liver disease 29.7 ADIPOQ INS LEP MTTP PPARG
11 arteries, anomalies of 29.7 ADIPOQ INS LEP PPARG SERPINE1
12 glucose intolerance 29.5 ADIPOQ INS LEP PPARG SLC2A4
13 gestational diabetes 29.5 ADIPOQ INS LEP SLC2A4
14 fatty liver disease, nonalcoholic 1 29.5 ADIPOQ INS LEP MTTP
15 hypertension, essential 29.4 ADIPOQ INS LEP SERPINE1
16 morbid obesity 29.4 ADIPOQ INS LEP PPARG
17 acanthosis nigricans 29.3 ADIPOQ INS LEP PPARG
18 atherosclerosis susceptibility 29.3 ADIPOQ INS PPARG SERPINE1
19 cerebrovascular disease 29.3 ADIPOQ INS MEG3 SERPINE1
20 pre-eclampsia 29.3 ADIPOQ LEP SERPINE1
21 diabetes mellitus, insulin-dependent 29.2 INS LEP MEG3
22 familial partial lipodystrophy 29.2 INS LEP PPARG
23 coronary heart disease 1 29.2 ADIPOQ INS SERPINE1
24 lipid metabolism disorder 29.2 ADIPOQ INS LEP MTTP PPARG SERPINE1
25 arteriosclerosis 29.2 ADIPOQ INS PPARG SERPINE1
26 alstrom syndrome 29.2 INS LEP
27 prader-willi syndrome 29.1 ADIPOQ INS LEP
28 osteoporosis 29.0 ADIPOQ HSD11B1 INS LEP PPARG
29 vascular disease 28.9 ADIPOQ INS PPARG SERPINE1
30 hyperglycemia 28.9 ADIPOQ INS LEP PPARG
31 inherited metabolic disorder 28.8 ADIPOQ INS LEP
32 maturity-onset diabetes of the young, type 1 28.7 ADIPOQ INS LEP PPARG SERPINE1
33 severe pre-eclampsia 28.6 ADIPOQ LEP
34 body mass index quantitative trait locus 11 28.5 ADIPOQ HSD11B1 INS LEP MTTP PPARG
35 diabetes mellitus 28.4 ADIPOQ INS LEP MEG3 PPARG SERPINE1
36 glucose metabolism disease 28.2 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
37 overnutrition 28.2 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
38 diabetes mellitus, noninsulin-dependent 27.9 ADIPOQ HSD11B1 INS LEP MTTP PPARG
39 abdominal obesity-metabolic syndrome 3 12.3
40 gracile syndrome 11.2
41 polycystic ovary syndrome 11.2
42 gallbladder disease 1 11.0
43 smith-lemli-opitz syndrome 10.7
44 diabetes mellitus, noninsulin-dependent, 1 10.7
45 glaucoma, normal tension 10.7
46 diabetes mellitus, noninsulin-dependent, 5 10.7
47 47, xxy 10.7
48 coronary artery anomaly 10.3
49 hyperuricemia 10.3
50 schizophrenia 10.2

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity


Clinical features from OMIM:

605552

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

32
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 abdominal obesity 32 HP:0012743

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ADIPOQ HSD11B1 INS LEP MTTP PPARG
2 growth/size/body region MP:0005378 10.06 ADIPOQ HSD11B1 INS LEP MTTP PPARG
3 adipose tissue MP:0005375 10.05 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
4 homeostasis/metabolism MP:0005376 10.01 ADIPOQ HSD11B1 INS LEP MTTP PPARG
5 hematopoietic system MP:0005397 9.98 ADIPOQ HSD11B1 INS LEP MTTP PPARG
6 endocrine/exocrine gland MP:0005379 9.95 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
7 immune system MP:0005387 9.91 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
8 liver/biliary system MP:0005370 9.86 ADIPOQ HSD11B1 INS LEP MTTP PPARG
9 integument MP:0010771 9.8 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
10 muscle MP:0005369 9.63 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
11 nervous system MP:0003631 9.5 ADIPOQ HSD11B1 INS LEP MTTP PPARG
12 renal/urinary system MP:0005367 9.02 ADIPOQ INS LEP PPARG SERPINE1

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMedHealth treatment related to Abdominal Obesity-Metabolic Syndrome 1: 63

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking.If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar.Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Search Clinical Trials , NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 29 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

41
Liver, Endothelial, Heart, Ovary, Prostate, Breast, Testes

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 61)
# Title Authors Year
1
The question of metabolic syndrome X. ( 26631307 )
2015
2
Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X. ( 26413164 )
2015
3
Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. ( 23923606 )
2013
4
Central retinal artery occlusion in a patient with metabolic syndrome x. ( 22737328 )
2010
5
Anaesthetic considerations in metabolic syndrome X. ( 20532086 )
2010
6
Beneficial effects of modified egg* on oxidative stress in F1- generation of metabolic syndrome-X induced Wistar rat. ( 19374165 )
2009
7
Cardiac syndrome X versus metabolic syndrome X. ( 17010457 )
2007
8
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( 17475465 )
2007
9
[The metabolic syndrome X or insulin resistance syndrome]. ( 17304724 )
2007
10
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. ( 16941796 )
2006
11
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. ( 16416266 )
2006
12
Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. ( 16999025 )
2006
13
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 15833894 )
2005
14
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. ( 15734832 )
2005
15
Pathophysiology of metabolic syndrome X and its links to the perinatal period. ( 15925303 )
2005
16
Swiss Medical Weekly Young Investigator's Award 2003: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 15243846 )
2004
17
Metabolic syndrome X: an inflammatory condition? ( 14972097 )
2004
18
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. ( 15470277 )
2004
19
Low-flow vascular remodeling in the metabolic syndrome X. ( 14644764 )
2004
20
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. ( 12697574 )
2003
21
Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions. ( 12781862 )
2003
22
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( 15028595 )
2003
23
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 12756274 )
2003
24
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. ( 12946657 )
2003
25
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. ( 14574352 )
2003
26
Metabolic syndrome X is common in Indians: but, why and how? ( 14719590 )
2003
27
Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. ( 12537988 )
2003
28
Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 12947532 )
2003
29
Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. ( 11856814 )
2002
30
The metabolic syndrome X and peripheral cortisol synthesis. ( 12397528 )
2002
31
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. ( 12512799 )
2002
32
Is metabolic syndrome X an inflammatory condition? ( 12486208 )
2002
33
Obesity, metabolic syndrome X, and inflammation. ( 11985951 )
2002
34
Metabolic syndrome X--high risk factor for acute myocardial infarction and its complications. ( 12137304 )
2002
35
Molecular mechanism of vascular disease in metabolic syndrome X. ( 11872360 )
2002
36
Metabolic syndrome X is common in South Asians, but why and how? ( 12297221 )
2002
37
Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. ( 11958275 )
2001
38
Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. ( 15573024 )
2001
39
Unravelling metabolic syndrome X. ( 11427370 )
2001
40
Steroid metabolism in metabolic syndrome X. ( 11469814 )
2001
41
Insulin resistance: the metabolic syndrome X ( 10713753 )
2000
42
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. ( 11057441 )
2000
43
Metabolic syndrome X: a review. ( 10863169 )
2000
44
Metabolic syndrome X and fibrinolytic disturbances. ( 10870268 )
2000
45
Liver pathology and the metabolic syndrome X in severe obesity. ( 10323371 )
1999
46
Hypothalamic origin of the metabolic syndrome X. ( 10842670 )
1999
47
The metabolic syndrome X. ( 10842649 )
1999
48
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. ( 10483984 )
1999
49
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. ( 10842660 )
1999
50
Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. ( 10189006 )
1999

Variations for Abdominal Obesity-Metabolic Syndrome 1

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 ADIPOQ INS LEP PPARG SLC2A4
2
Show member pathways
12.6 ADIPOQ LEP PPARG SLC2A4
3
Show member pathways
12.45 ADIPOQ INS LEP SLC2A4
4 12.2 ADIPOQ INS PPARG SLC2A4
5
Show member pathways
12.07 ADIPOQ INS LEP PPARG SLC2A4
6
Show member pathways
11.92 INS LEP SLC2A4
8
Show member pathways
11.85 ADIPOQ INS PPARG
9
Show member pathways
11.59 ADIPOQ INS SLC2A4
10 11.38 ADIPOQ LEP SLC2A4
11 11.28 LEP SLC2A4
12 11.26 INS LEP
13 11.22 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
14 11.19 INS SLC2A4
15 11 INS SLC2A4
16 10.9 ADIPOQ LEP PPARG
17 10.66 INS SLC2A4
18 10.6 ADIPOQ LEP PPARG SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.85 HSD11B1 LEP MTTP PPARG
2 regulation of signaling receptor activity GO:0010469 9.8 ADIPOQ INS LEP SERPINE1
3 fatty acid beta-oxidation GO:0006635 9.61 ADIPOQ LEP
4 response to activity GO:0014823 9.61 ADIPOQ LEP
5 placenta development GO:0001890 9.6 LEP PPARG
6 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.59 ADIPOQ PPARG
7 positive regulation of glucose import GO:0046326 9.58 ADIPOQ INS
8 brown fat cell differentiation GO:0050873 9.58 ADIPOQ SLC2A4
9 response to ethanol GO:0045471 9.58 ADIPOQ LEP SLC2A4
10 positive regulation of interleukin-8 production GO:0032757 9.57 ADIPOQ SERPINE1
11 lipoprotein transport GO:0042953 9.56 MTTP PPARG
12 positive regulation of cellular protein metabolic process GO:0032270 9.54 ADIPOQ INS
13 cellular response to insulin stimulus GO:0032869 9.54 ADIPOQ PPARG SLC2A4
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.52 INS LEP
15 regulation of fat cell differentiation GO:0045598 9.51 LEP PPARG
16 response to nutrient GO:0007584 9.5 ADIPOQ LEP PPARG
17 fatty acid oxidation GO:0019395 9.48 ADIPOQ PPARG
18 negative regulation of gluconeogenesis GO:0045721 9.46 ADIPOQ INS
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ PPARG
20 glucose metabolic process GO:0006006 9.33 ADIPOQ INS LEP
21 negative regulation of acute inflammatory response GO:0002674 9.26 INS PPARG
22 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SERPINE1
23 glucose homeostasis GO:0042593 9.02 ADIPOQ INS LEP PPARG SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....